Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia.

Ballester LY, Penas-Prado M, Leeds NE, Huse JT, Fuller GN.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002378. doi: 10.1101/mcs.a002378. Print 2018 Apr.

2.

Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas.

Sippl C, Urbschat S, Kim YJ, Senger S, Oertel J, Ketter R.

Oncol Lett. 2018 Feb;15(2):1600-1606. doi: 10.3892/ol.2017.7490. Epub 2017 Nov 24.

3.

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

Jain P, Silva A, Han HJ, Lang SS, Zhu Y, Boucher K, Smith TE, Vakil A, Diviney P, Choudhari N, Raman P, Busch CM, Delaney T, Yang X, Olow AK, Mueller S, Haas-Kogan D, Fox E, Storm PB, Resnick AC, Waanders AJ.

Oncotarget. 2017 Sep 15;8(49):84697-84713. doi: 10.18632/oncotarget.20949. eCollection 2017 Oct 17.

4.

Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.

Pan Y, Bush EC, Toonen JA, Ma Y, Solga AC, Sims PA, Gutmann DH.

Oncotarget. 2017 Apr 18;8(32):52474-52487. doi: 10.18632/oncotarget.17193. eCollection 2017 Aug 8.

5.

mTOR activation is increased in pilocytic astrocytomas from older adults compared with children.

Johnson MD, O'Connell M, Walter K, Silberstein H.

Surg Neurol Int. 2017 May 26;8:85. doi: 10.4103/sni.sni_367_16. eCollection 2017.

6.

Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.

Ricker CA, Pan Y, Gutmann DH, Keller C.

Front Oncol. 2016 Dec 20;6:259. doi: 10.3389/fonc.2016.00259. eCollection 2016. Review.

7.

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.

Rogers HA, Estranero J, Gudka K, Grundy RG.

Oncotarget. 2017 Jan 10;8(2):2083-2095. doi: 10.18632/oncotarget.13781. Review.

8.

KIAA0247 suppresses the proliferation, angiogenesis and promote apoptosis of human glioma through inactivation of the AKT and Stat3 signaling pathway.

Tan Y, Huang N, Zhang X, Hu J, Cheng S, Pi L, Cheng Y.

Oncotarget. 2016 Dec 27;7(52):87100-87113. doi: 10.18632/oncotarget.13527.

9.

Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.

Alvarenga AW, Machado LE, Rodrigues BR, Lupinacci FC, Sanemastu P, Matta E, Roffé M, Torres LF, da Cunha IW, Martins VR, Hajj GN.

J Histochem Cytochem. 2017 Feb;65(2):93-103. doi: 10.1369/0022155416675850. Epub 2016 Oct 28.

10.

Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.

Lin FY, Bergstrom K, Person R, Bavle A, Ballester LY, Scollon S, Raesz-Martinez R, Jea A, Birchansky S, Wheeler DA, Berg SL, Chintagumpala MM, Adesina AM, Eng C, Roy A, Plon SE, Parsons DW.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001057. doi: 10.1101/mcs.a001057.

11.

MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1.

Mao Y, Li L, Liu J, Wang L, Zhou Y.

Oncotarget. 2016 Aug 9;7(32):51223-51236. doi: 10.18632/oncotarget.9981.

12.

Contextual signaling in cancer.

Smithson LJ, Anastasaki C, Chen R, Toonen JA, Williams SB, Gutmann DH.

Semin Cell Dev Biol. 2016 Oct;58:118-26. doi: 10.1016/j.semcdb.2016.06.002. Epub 2016 Jun 3. Review.

13.

Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas.

Garcia MA, Solomon DA, Haas-Kogan DA.

Future Oncol. 2016 Jun;12(12):1493-506. doi: 10.2217/fon-2016-0039. Epub 2016 Apr 13. Review.

14.

Diffuse leptomeningeal spread of supratentorial recurrent pilocytic astrocytoma in a child.

Raheja A, Singh PK, Nambirajan A, Sharma MC, Sharma BS.

J Pediatr Neurosci. 2015 Oct-Dec;10(4):408-11. doi: 10.4103/1817-1745.174452. No abstract available.

15.

Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P.

Sci Rep. 2016 Feb 19;6:21252. doi: 10.1038/srep21252.

16.

Comparative transcriptomics reveals similarities and differences between astrocytoma grades.

Seifert M, Garbe M, Friedrich B, Mittelbronn M, Klink B.

BMC Cancer. 2015 Dec 16;15:952. doi: 10.1186/s12885-015-1939-9.

17.

Model-Based Evaluation of Spontaneous Tumor Regression in Pilocytic Astrocytoma.

Buder T, Deutsch A, Klink B, Voss-Böhme A.

PLoS Comput Biol. 2015 Dec 10;11(12):e1004662. doi: 10.1371/journal.pcbi.1004662. eCollection 2015 Dec.

18.

RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.

Solga AC, Pong WW, Kim KY, Cimino PJ, Toonen JA, Walker J, Wylie T, Magrini V, Griffith M, Griffith OL, Ly A, Ellisman MH, Mardis ER, Gutmann DH.

Neoplasia. 2015 Oct;17(10):776-88. doi: 10.1016/j.neo.2015.10.002.

19.

Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.

Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG.

J Clin Oncol. 2015 Sep 20;33(27):2986-98. doi: 10.1200/JCO.2014.59.9217. Epub 2015 Aug 24. Review.

20.

Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.

Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE.

Oncogene. 2016 Apr 28;35(17):2186-96. doi: 10.1038/onc.2015.279. Epub 2015 Jul 27.

Supplemental Content

Support Center